A B S T R A C T This study was desigined to investigate the role of dopaminergic mechanisms in the control of aldosterone secretion in man. Five normal male subjects in metabolic balance at 150 meq sodium/d and 60 meq potassium/d constant intake received the specific dopamine antagonist, metoclopramide, 10 mg i.v. on 2 consecutive d. On the 1st d, the subjects received an infusion of 5% glucose solution (vehicle) from 60 min before to 60 min after metoclopramide administration; on the 2nd d, an infusion of dopamine 4 jig/kg per min was substituted for vehicle. Meto-clopramide in the presence of vehicle increased plasma aldosterone concentrations from 2.4±1.1 to a maximum of 17.2±2.8 ng/100 ml (P < 0.01) and serum prolactin concentrations from 7.5±5.0 to a maximum of 82.2±8.7 ng/ml (P < 0.01). Dopamine 4 ,ug/kg per min did not alter basal plasma aldosterone concentrations, but blunted the aldosterone responses to metoclopramide significantly; in the presence of dopamine, plasma aldosterone concentrations increased from 3.1±0.5 to 6.2±1.4 ng/100 ml (P < 0. Metoclopramide 10 mg i.v. was administered to five additional subjects after pretreatment with the dopamine agonist, bromocriptine, 2.5 mg or placebo at 6 p.m., midnight, and 6 a.m. before study. Bromocriptine suppressed basal serum prolactin levels and completely inhibited the prolactin responses to metoclopramide. In contrast, bromocriptine did not alter basal plasma aldosterone concentrations or the aldosterone responses to metoclopramide. Plasmiia renin activity, plasma cortisol, and serum potassium concentrations were unchanged by metoclopramide, dopamine, or bromocriptine. 
A B S T R A C T This study was desigined to investigate the role of dopaminergic mechanisms in the control of aldosterone secretion in man. Five normal male subjects in metabolic balance at 150 meq sodium/d and 60 meq potassium/d constant intake received the specific dopamine antagonist, metoclopramide, 10 mg i.v. on 2 consecutive d. On the 1st d, the subjects received an infusion of 5% glucose solution (vehicle) from 60 min before to 60 min after metoclopramide administration; on the 2nd d, an infusion of dopamine 4 jig/kg per min was substituted for vehicle. Meto- clopramide in the presence of vehicle increased plasma aldosterone concentrations from 2.4±1.1 to a maximum of 17 .2±2.8 ng/100 ml (P < 0.01) and serum prolactin concentrations from 7 .5±5.0 to a maximum of 82.2±8.7 ng/ml (P < 0.01). Dopamine 4 ,ug/kg per min did not alter basal plasma aldosterone concentrations, but blunted the aldosterone responses to metoclopramide significantly; in the presence of dopamine, plasma aldosterone concentrations increased from 3.1±0.5 to 6.2±1.4 ng/100 ml (P < 0.05) in response to metoclopramide. The incremental aldosterone responses to metoclopramide were significantly lower in the presence of dopamine than with vehicle. Dopamine 4 ,ug/kg per min suppressed basal prolactin to <3 ng/ml and inhibited the prolactin responses to metoclopramide; serum prolactin concentrations increased to a maximum of8.5±2.3 ng/ml with metoclopramide in the presence of dopamine.
The subjects were studied in the same manner except that dopamine 2 jig/kg per min was adminisDr. Carey is an Established Investigator of the American Heart Association.
Receivedfor publication 26 December 1.979 and itl revised forimi 18 March 1980. 10 tered instead of the 4-,ug/kg per min dose. Dopamine 2 Ag/kg per min attenuated the aldosterone and prolactin responses to metoclopramide, but was less effective than the 4-,ug/kg per min dose of dopamine.
Metoclopramide 10 mg i.v. was administered to five additional subjects after pretreatment with the dopamine agonist, bromocriptine, 2.5 mg or placebo atINTRODUCTION Metoclopramide [N-diethylaminoethyl)-2-miiethoxy -4-aminio-5-chlorobenzamide], a procainamide derivative, is a comiipetitive antagonist of dopamine in the cenitral nervous svstem (1-4), gut (5) , and cardliovascuilar system (6) . Metoclopramide stimulates prolactini secretion from the pituitary gland in vivo in experimental animals and man (7) (8) (9) (10) (11) (12) (13) , and antagonizes the inhibitory effect of dopamine on prolactin release in vitro (14) . Of the dopamine receptor antagonists cur-rently available, metoclopramide appears to be the most specific (15) .
Recent studies from this laboratory (16) have demonstrated that metoclopramide stimulates aldosterone production in normal man. The increase in aldosterone production could not be attributed to increase in any of the known factors that stimulate aldosterone or to increases in prolactin. On the other hand, bromocriptine (2-brom-a-ergocryptine), a specific dopamine agonist, neither decreased basal aldosterone production nor inhibited angiotensin II-induced aldosterone secretion. Taken together, these observations suggested that, in normal man, aldosterone production may be under maximum "tonic" dopaminergic inhibition, which can be overridden by the renin-angiotensin system (16) .
The present study was designed to investigate further the role of dopaminergic mechanisms in the control of aldosterone production in normal man. The rationale for this study may be stated simply. If metoclopramide stimulates aldosterone production by antagonizing dopamine at dopamine receptor sites, then metoclopramide-induced aldosterone production should be inhibited by dopaminergic agonists. Thus, the effects ofboth dopamine and the dopamine agonist, bromocriptine, on metoclopramide-induced increases in plasma aldosterone concentration were determined. During these experiments, potassium, ACTH (as reflected by plasma cortisol concentratio-ns), and the renin-angiotensin system, which are all known to influence aldosterone, and prolactin, an index of dopamine receptor effects, were also studied.
METHODS
10 normal white male volunteer subjects, 20-30 yr, with normal arterial blood pressure and no history of renal disease were studied. The protocol was approved by the Human Experimentation Committee ofthe University ofVirginia Medical Center and written informed consent was obtained from all subjects. Before study, the subjects were placed on a constant diet containing 150 meq of sodium, 60 meq of potassium, 1 g of protein/kg, and 2,680 cal/d for 5 d at the Clinical Research Center. Consecutive 24-h urine samples were collected for the first 4 d of the diet, and consecutive 12-h urine samples were collected for the remainder of each study and were analyzed for sodium, potassium, and creatinine.
Metoclopramideldopamine studies. Five of the subjects were studied in the following manner. No food was given after midnight before study day 1, when the subjects assumed the supine position until completion ofthe study. At 6:00 a.m. of study day one, a heparin lock for obtaining blood samples was placed in the left antecubital vein and an intravenous infusion of 5% glucose solution (D5W)' at 1 ml/min was begun in the right antecubital vein. At 6:30 a.m., the subjects completed their 12-h urine collections and blood pressure 'Abbreviation used in this paper: D5W, 5% glucose solution.
monitoring with an Arteriosonde (Hoffman-LaRoche, Inc., Nutley, N. J.) was initiated and continued every 2 min until completion of study. At 7:00 a.m., control blood samples were obtained for determination of serum sodium, potassium, and prolactin concentrations, and plasma renin activity, cortisol, and aldosterone concentrations. After completion of blood sampling at 7:00 a.m., an intravenous infusion of D5W (vehicle) at 0.1 ml/min was initiated with a Harvard infusion pump (Harvard Apparatus Co., Inc., S. Natick, Mass.) and was continued for 120 min (-60-60 min of the study). Blood sampling was repeated at 7:30 and 8:00 a.m. (-30 and 0 min of the study). After completion of the blood sampling at 8:00 a.m., an intravenous bolus dose of metoclopramide (10 mg) was given. Blood samples were then obtained at 10, 20, 30, and 60 min (8:10, 8:20, 8:30 , and 9:00 a.m.) after metoclopramide injection. At 9:00 a.m., the D5W (vehicle) infusion was discontinued and further blood sampling accomplished at 9:30 and 10:00 a.m. (90 and 120 min after metoclopramide administration).
After completion of the study at 10:00 a.m., the subjects continued on the constant diet and urine collections. On study day 2, an identical protocol as for study day one was carried out except that, instead of D5W vehicle, dopamine hydrochloride 2 ,ug/kg per min was infused for 120 min beginning at 7:00 a.m. The diet wvas discontinued and the subjects were discharged from the Clinical Research Center after completion of the final urine collection at 6:30 p.m. on study day 2. The total volume of blood obtained from each subject during the 2nd study was 500 ml.
After a 4-6 wk interval on an ad lib. diet, the same subjects were placed again on the same constant diet at the Clinical Research Center for 5 d before study. Urine collections were obtained as before. The subjects then underwent an identical protocol on study days 1 and 2 as described above for the metoclopramide/dopamine studies except that 4 ,ug/kg per min of dopamine was substituted for the 2 ,ug/kg per min quantity of dopamine administered on study day 2.
Metoclopranmidelbromocriptine studies. The remaining five subjects were studied with an identical protocol as for the metoclopramide/dopamine studies with the following exceptions. Dopamine or vehicle were not administered. Instead, the subjects received placebo capsules orally at 6:00 p.m. and midnight before study day 1 and at 6:00 a.m. on study day 1. At 7:00 and 7:30 a.m. on study day 1, control blood samples were obtained and the intravenous bolus dose of metoclopramide (10 mg ) was given at 7:30 a.m. Blood samples were obtained at 10, 20, 30, 60 , and 90 min (7:40, 7:50, 8:00, 8:30, and 9:00 a.m.) after metoclopramide administration. At 6:00 p.m. and midnight on study day 1, and at 6:00 a.m. on study day 2, bromocriptine 2.5 mg was administered orally. On study day 2, an identical protocol as for study day 1 was accomplished. On study day 2, to prevent any postural hypotension as a result of the treatment with bromocriptine, the subjects remained supine from the end of the study at 9:00 a.m. until noontime. Blood pressure was measured every 30 min with a mercury sphygmomanometer. The diet was discontinued and the subjects were discharged from the Clinical Research Center after completion of the final urine collection at 6:30 p.m. on study day 2. The total volume of blood obtained from each subject during the 2-d study was 320 ml.
During these studies, blood pressure was monitored with an Arteriosonde automatic ultrasonic blood pressure recorder. A blood pressure cuff (with a wide approximately two thirds of the width of the arm and a length sufficient for the bladder to completely encircle the arm) was wrapped snugly around the left arm. The Arteriosonde was calibrated daily against a random zero mercurv sphygmomanometer. In the metoDopaminergic Control of Aldosterone I 1 clopramide/dopamine study, control blood pressure readings are expressed as the mean of 15 readings that were obtained between -120 and -90 min (6:30-7:00 a.m. = -90 control value) and between -90 and -60 min (7:00-7:30 a.m. = -60 control value) before administration of any intravenous pharmacological agents. After the control period, blood pressures are expressed as the mean of 15 readings for each 30- (17) . After incubation, plasma renin activity was determined by radioimmunoassay ofangiotensin I generated as described by Sealey et al. (18) . Plasma cortisol was measured by specific radioimmunoassay (19) . Serum prolactin was measured by the method of Sinha et al. (20 
RESULTS
Characteristics of the subjects before the metoclopramide/dopamine and metoclopramidelbromocriptine studies. The characteristics ofthe subjects in sodium balance on the 5th d of normal sodium intake (150 meq/d) before each set of experiments are summarized in Table I 4 ,ug/kg per min, 3 .1+0.9 ng/100 ml, were significantly lower than in the presence of dopamine 2 ,ug/kg per min, 5.0±0.8 ng/100 ml (P < 0.05).
Serum prolactin concentrations are shown in Fig. 2 , right-hand panel. Vehicle infusion was not associated with any significant change in serum prolactin concentrations. Metoclopramide increased prolactin levels (P < 0.01) at 10 min and to a peak value (P < 0.01) at 30 min. Prolactin concentrations were still elevated at 60 min, but decreased at 90 min (40 min after cessation of vehicle infusion). Dopamine (4 ,ug/kg per min) decreased basal prolactin levels and inhibited the prolactin response to metoclopramide. After 30 min of dopamine infusion, prolactin had decreased to undetectable levels (<3 ng/ml) and remained suppressed at 0 min before metoclopramide administration. There was a peak increase of serum prolactin concentrations (P < 0.05) at 20 min in response to metoclopramide, but at 60 min the prolactin was just barely detectable. After the discontinuation of the dopamine infusion, there was a marked increase of serum prolactin concentrations (P < 0.01).
During the metoclopramide/dopamine studies at both dose levels of dopamine, there were no changes in plasma renin activity, plasma cortisol, serum sodium, or potassium concentrations in response to metoclopramide, dopamine, or vehicle (data not shown). Metoclopramidelbromocriptine study (Fig. 3) . Supine blood pressures of the remaining five subjects are depicted in Fig. 3 , left-hand panel, The -30 control values for blood pressure were similar after placebo and bromocriptine administration, but the zero control values for systolic and diastolic pressure were lower after bromocriptine than placebo (P < 0.05). In response to metoclopramide, there was no change in blood pressure after placebo or bromocriptine administration from respective zero control values.
Plasma aldosterone concentrations are shown in Fig.  3 , middle panel. In response to metoclopramide, plasma aldosterone concentrations increased (P < 0.05) at 10 min and remained elevated from control values for 90 min. Control aldosterone values after placebo and bromocriptine were similar. After bromocriptine, metoclopramide increased aldosterone concentrations (P < 0.05) at 10 min, and aldosterone remained elevated for the duration ofthe study. No significant differences in aldosterone values were observed in response to metoclopramide whether the subjects were pretreated with placebo or bromocriptine.
Serum prolactin concentrations are shown in Fig. 3 , right-hand panel. At 10 min after metoclopramide administration, serum prolactin levels increased (P < 0.005). Serum prolactin increased further (P < 0.001) at 30 min after metoclopramide and remained elevated for the remainder of the study period. Bromocriptine consistently suppressed serum prolactin concentrations to <3 ng/ml (P < 0.001) and metoclopramide failed to increase prolactin in bromocriptine-treated subjects. Concentrations ofplasma cortisol, serum sodium, and potassium, and plasma renin activity did not change significantly at any time during the metoclopramide/ bromocriptine studies (data not shown).
DISCUSSION
The present investigation was designed to determine the effects of dopamine agonists on metoclopramideinduced aldosterone secretion in normal man. Two agonists, dopamine and bromocriptine, were selected for study. The first agent, bromocriptine, is an ergot derivative and was developed by 
. However, the mechanism of action of bromocriptine was determined later to be a prolonged dopaminergic response (22) (23) (24) . Bromocriptine acts as a dopamine agonist in the central nervous system (22, 23) , at the pituitary gland to inhibit prolactin release (14, (25) (26) (27) , and on peripheral vascular dopamine receptors to produce vasodilitation of renal and mesenteric arteries (28) . Bromocriptine has been demonstrated to bind to dopamine receptors in radioreceptor assays using membranes from brain homogenates (29) . Bromocriptine also is a weak alpha-adrenergic and serotoninergic antagonist, but it is unlikely that these actions would mediate the observed changes because low doses were used in the present studies (23) . The other agent used in these studies was dopamine, a precursor of the sympathetic neurotransmitter, norepinephrine. Dopamine is possibly a major transmitter of the peripheral antonomic nervous system (30) . Although dopamine possesses weak alpha-and beta-adrenergic activities, in the quantities employed here little or no adrenoreceptor effects would be expected to occur (31) . Furthermore, there is no precedent for suppression of aldosterone secretion by sympathomimetic agents. The dopaminergic antagonist, metoclopramide, and the dopaminergic agonists, bromocriptine and dopamine, employed in these studies were chosen because of their relative selectivity for dopamine receptors, but it is recognized that no pharmacological agent is completely specific. This investigation demonstrated that dopaminergic mechanisms affect the adrenal gland as evidenced by a maximum tonic inhibitory influence on aldosterone production in man. Basal plasma aldosterone concentrations were not decreased by the administration of dopamine. However, metoclopramide-induced increases in plasma aldosterone concentration were inhibited by dopamine. Although this effect could be related to some indirect effect of dopamine, this possibility seems unlikely. None of the known mediators of aldosterone secretion changed during the administration of metoclopramide alone or in the presence of dopamine. Although complete obliteration of the aldosterone response to metoclopramide was not achieved even with the highest dose of dopamine employed, the inhibition of metoclopramide-induced increases in plasma aldosterone concentration by dopamine was dose-dependent with the larger quantity of dopamine inhibiting the aldosterone response more completely. These results strongly suggest that the aldosterone response to metoclopramide is mediated by an antagonist activity at dopamine receptors.
Unexpectedly, metoclopramide-induced increases in plasma aldosterone concentration were not inhibited by bromocriptine. In fact, the aldosterone responses to metoclopramide were virtually identical at all time points from 0 to 90 min after administration of bromocriptine or its placebo. This observation may explain our previous finding (16) that bromocriptine did not inhibit the adrenal steroidogenic response to angiotensin II. A possible explanation for this finding might be that bromocriptine acts as a renal vasodilator, stimulating renin release and, thus, augmenting aldosterone secretion. However, the absence of change in plasma renin activity with bromocriptine administration virtually excludes this mechanism.
The finding that metoclopramide-induced aldosterone production is inhibited by dopamine but not by bromocriptine raises interesting questions concerning the pharmacological characteristics of putative dopamine receptors in the adrenal zona glomerulosa as compared with those in the pituitary gland. The efficacy of the dopamine agonists and antagonist used in this study on pituitary dopamine receptors was monitored by means of changes in serum prolactin concentration. In response to metoclopramide, serum prolactin concentrations increased markedly. Dopamine decreased basal prolactin to levels below detection limits of our assay and inhibited prolactin responses to metoclopramide in a dose-dependent manner with nearly complete inhibition at 4 ,ug/kg per min. Similarly, bromocriptine decreased basal prolactin below detectable limits and obliterated the prolactin response to metoclopramide. Thus, the pituitary dopamine receptor was inhibited by both dopamine and bromocriptine, whereas only dopamine was effective on the adrenal response.
Recently, Kebabian and Calne (32) 
